Onasemnogene abeparvovec for the treatment of spinal muscular atrophy. (2nd September 2022)

• Record Type: Journal Article
• Authors: McMillan, Hugh J.; Proud, Crystal M.; Farrar, Michelle A.; Alexander, Ian E.; Muntoni, Francesco; Servais, Laurent
• Is Part Of: Expert opinion on biological therapy. Volume 22:Number 9(2022)
• Page Start: 1075
• Page End: 1090
• Publication Date: 2022-09-02
• Subjects: Adeno-associated viral vector -- disease-modifying treatments -- gene therapy -- motor milestones -- newborn screening -- neurodegenerative disorders -- onasemnogene abeparvovec -- spinal muscular atrophy -- survival motor neuron -- vector genomes; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2022.2066471
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Introduction: Gene therapy for spinal muscular atrophy (SMA) represents a significant milestone in the treatment of neurologic diseases. SMA is a neurodegenerative disease that results in motor neuron loss because of mutations of the survival motor neuron 1 gene, which directs survival motor neuron (SMN) protein production. Onasemnogene abeparvovec, a one-time gene replacement therapy, delivers a functional transgene to restore SMN protein expression. Onasemnogene abeparvovec has demonstrated improved survival and motor milestone achievements for presymptomatic infants and patients with SMA type 1. Areas covered: This expert review describes the current state of gene therapy for SMA, reviews the mechanism of and clinical experience with onasemnogene abeparvovec, explains future efforts to expand applications of gene therapy for SMA, and provides context for developing gene therapy for other conditions. Expert opinion: Onasemnogene abeparvovec has demonstrated efficacy in clinical trials and, because of this, is a valuable treatment option for patients with symptomatic infantile SMA and those identified by newborn screening. Gene therapy is still in its infancy, and challenges and uncertainties associated with transgene delivery must be addressed. With ongoing development of vector technology, more specific tissue tropism, reduced 'off-target' effects, and an enhanced safety profile will continue to evolve.